Developer docs
API playgroundTry for free, no card

Search company profiles

Q Bio

Full company profile

uuid0000ggs

Namestring
Q Bio
Legal namestring
Q Bio, Inc.
Websiteurl
q.bio
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Q Bio, founded in 2015 and headquartered in Redwood City, California, is a private health technology company building a Clinical Digital Twin Platform that integrates whole-body MRI, biomarker analysis, genetic screening, wearable data, and physician review into a single longitudinal health record. The core product is the Q Exam, a 75-minute in-clinic service priced at $3,495 per annual membership that captures non-contrast whole-body MRI imaging (9,500+ images across 10 sequences), 120+ blood and urine biomarkers, 163 clinically actionable genetic markers, vitals, and a 45-minute physician data review. The Q Bio Health Dashboard unifies these inputs into a longitudinal record organized across nine body systems, enabling year-over-year comparison for returning members. Constellation, the company's FDA 510(k)-cleared AI image-analysis software, performs automated organ and tissue segmentation from MRI scans and produces standardized measurements that make cross-visit comparison operationally viable.

Q Bio operates a dual go-to-market model. On the consumer side, individuals book the Q Exam directly at the Redwood City flagship clinic, which runs three appointment slots per day Monday through Friday. On the enterprise side, Q Bio partners with concierge medicine practices, executive health programs, longevity clinics, health systems, and employer member programs to deploy the Q Exam under the partner's brand, with Q Bio supplying the protocol, data infrastructure, and Dashboard layer. Enterprise deployments typically move from kickoff to live operation in approximately 4-6 months and are evaluated for international rollout on a partner-by-partner basis. The company does not accept insurance but the service qualifies for HSA/FSA reimbursement.

The company has raised approximately $91M in cumulative venture funding across rounds in 2016 ($7.5M), 2018 ($16.5M), 2020 ($40M), and 2024 ($27M), with investors including Andreessen Horowitz, Founders Fund, Khosla Ventures, Kaiser Permanente, and TELUS Global Ventures. Leadership combines Stanford, Harvard, MIT, UnitedHealth, Abbott, and Dexcom alumni. Q Bio holds no public listing and operates as Q Bio, Inc., a Delaware corporation.

Short descriptiontext

Q Bio operates a Clinical Digital Twin Platform that combines whole-body MRI, 120+ biomarkers, 163-gene genetic screening, wearable data, and physician review into a single longitudinal health record, delivered directly at its Redwood City clinic and through enterprise health partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
whole-body MRI screening, preventive health platform, AI medical imaging, longitudinal health records, biomarker genetic testing
Industry2 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medical Laboratories621511
  • Diagnostic Imaging Centers621512
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Preventive Health Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Annual Q Exam Membership
TypeSubscription Recurring
Description

Individual consumers pay $3,495 USD annually for access to the Q Exam, which includes the 75-minute whole-body MRI, biomarkers (120+), genetics (163 genes), vitals, physician review, and 45-minute Data Review session. This is a recurring annual subscription model where members return for follow-up exams that compound in longitudinal value.

q.bio
2Enterprise Partner Deployment
TypeSubscription Recurring
Description

Q Bio provides its protocol, data infrastructure, and Q Bio Health Dashboard to enterprise health partners who deploy the Q Exam within their own branded clinical environments. Partners provide the clinical setting, physician relationship, and member base while Q Bio supplies the underlying platform. Commercial terms vary by partner type, scope, and geography.

q.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1Individual Annual Membership at Redwood City Clinic
ModelSubscriptionBilling cadenceAnnual
Notes

$3,495 USD per year — covers the complete Q Exam including whole-body MRI, 120+ biomarkers, 163 genetic markers, physician review, and 45-minute Data Review. HSA/FSA eligible. Cancellation within 48 hours incurs $500 fee.

q.bio
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 3 records shown
1Q Exam
Description

The comprehensive whole-body physical exam combining MRI, biomarkers, genetics, wearable data, and physician review.

q.bio
+2 more records
Core offering1 text field

Q Bio operates the Q Exam, a single 75-minute in-clinic comprehensive physical examination that captures non-contrast whole-body MRI (9,500+ images across 10 sequences), 120+ blood and urine biomarkers, 163-gene genetic screening, wearable data integration, and a 45-minute board-certified physician Data Review. Results are unified in the Q Bio Health Dashboard, a longitudinal clinical interface powered by the FDA 510(k)-cleared Constellation AI image-analysis software, enabling year-over-year comparison of every subsequent exam.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 9,500+ images captured per whole-body MRI scan
+3 more records
Product overview1 text field

Q Bio delivers a unified preventive health platform consisting of two integrated products: the Q Exam and the Q Bio Health Dashboard, powered by Constellation (FDA-cleared AI image-analysis software). The Q Exam is the in-clinic service capturing whole-body MRI, 120+ biomarkers, 163 genetic markers, wearable data, and physician review in a single 75-minute visit. The Q Bio Health Dashboard is the longitudinal product surface that unifies all captured inputs into a comparative clinical record, organized by nine body systems, accessible to both patients and clinicians. The Dashboard compounds in value with each subsequent exam, enabling year-over-year comparison of imaging, biomarker trends, and findings. The platform is available directly at Q Bio's Redwood City clinic and through enterprise partner deployments where Q Bio serves as the infrastructure layer beneath the partner's brand.

Product and service3 records
1Q Exam
CategoryPreventive Health Diagnostics
Description

A comprehensive in-clinic physical examination combining whole-body MRI (non-contrast, 9,500+ images across 10 sequences), 120+ blood and urine biomarkers, genetic screening of 163 clinically actionable genes, wearable device and prior medical record integration, and a 45-minute physician Data Review. Designed to establish a quantitative longitudinal health baseline captured in a single 75-minute visit for individual members and enterprise partner programs.

2Q Bio Health Dashboard
CategoryHealth Data Platform
Description

A longitudinal clinical interface that integrates imaging, biomarkers, genetics, wearable data, and physician-reviewed findings into a unified record organized by nine body systems. Delivered as both patient-facing and clinician-facing views, with year-over-year comparison capabilities, flagged out-of-range biomarkers, and shareable exports for the member's primary care team.

3Constellation
CategoryAI Medical Imaging Software
Description

Q Bio's FDA 510(k)-cleared image-analysis software for whole-body MRI processing. Uses AI/machine-learning methods to segment anatomical regions (lung, liver, brain, and other structures), quantify key measurements, and organize results for radiologist and physician review. Standardized measurements enable direct comparison across visits.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Michael Snyder, PhD, Chair of Genetics and Professor of Genomics at Stanford University, serves as Scientific Advisor and Co-founder of Q Bio. He previously served as director of the Yale Center for Genomics and Proteomics. Academic partnership provides scientific expertise and research credibility for Q Bio's quantitative biology approach.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Q Bio's Chief Medical Officer & Co-founder is a former Harvard Medical School faculty member and board-certified radiologist. Garry Choy, MD/MBA, Co-founder, is also Harvard-affiliated. Harvard partnership provides medical leadership and clinical research credibility.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical advisors with MGH affiliation provide medical expertise. MGH partnership contributes to Q Bio's clinical validation approach and reinforces the company's positioning within academic medical center circles.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Thomas Witzel, PhD, Chief Scientific Officer, has a key role in development of the Connectome MRI scanner and holds a PhD from Harvard-MIT Health Sciences & Technology. MIT affiliation contributes to Q Bio's MRI technology development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Prenuvo offers whole-body MRI screening combined with optional blood biomarkers as a direct-to-consumer preventive health service. It is the most direct competitor to Q Bio's Q Exam, with overlapping target customer (health-conscious affluent adults) and similar MRI-plus-biomarker value proposition, though without Q Bio's FDA-cleared AI platform layer.

TypeDirect peer
Description

Ezra provides whole-body MRI-based cancer and disease screening as a direct-to-consumer service using AI-assisted image analysis. It competes directly with Q Bio on MRI-based preventive screening for affluent consumers, with a similar AI-image-analysis value proposition though a narrower focus on oncology.

TypeDirect peer
Description

Human Longevity Inc (HLI) was a pioneer in combining whole-body MRI, whole-genome sequencing, and advanced biomarker testing into a comprehensive health assessment. It is a direct peer in offering integrated imaging-plus-genomic-plus-biomarker preventive health to high-net-worth and executive consumers.

4Function Health
TypeDirect peer
Description

Function Health offers a comprehensive blood-based biomarker panel (100+ markers) via direct-to-consumer subscription with physician review and longitudinal tracking. It competes directly with Q Bio on the 'comprehensive preventive panel + physician review + longitudinal record' value proposition, though without the imaging component.

TypeDirect peer
Description

InsideTracker provides blood-based biomarker analysis with personalized recommendations and longitudinal tracking for health optimization and longevity. It overlaps with Q Bio on the biomarker-tracking and longevity consumer segment, with similar longitudinal dashboard UX though narrower scope than Q Bio's MRI-based offering.

TypeDirect peer
Description

Forward Health operates membership-based preventive primary care clinics combining body scanning, blood testing, and AI-driven health insights. It is comparable to Q Bio as a tech-enabled preventive health membership model targeting affluent health-conscious consumers, with an owned-clinic distribution approach.

TypeDirect peer
Description

Fountain Life operates preventive health and longevity centers offering whole-body MRI, advanced biomarker panels, and genetic testing to affluent members. It is comparable to Q Bio as a premium integrated preventive health platform targeting the same longevity-focused, high-net-worth consumer segment.

8Tempus Labs
TypeBroad incumbent
Description

Tempus is a large precision medicine company applying AI to molecular and clinical data across oncology and beyond. While broader in scope and B2B-oriented, its AI-enabled diagnostics platform overlaps conceptually with Q Bio's Constellation AI image-analysis approach and longitudinal multimodal data positioning.

TypeBroad incumbent
Description

Color Health combines genetic testing with preventive health screening and virtual care delivery to employers, health systems, and consumers. It overlaps with Q Bio on the genetic-screening + preventive-health value proposition and shares the enterprise partner channel strategy with employers and health systems.

TypeEmerging player
Description

Lunit develops FDA-cleared AI medical imaging analysis software (notably for mammography and chest X-ray) sold to hospitals and radiology providers. It is comparable to Q Bio's Constellation as a regulatory-cleared AI image-analysis platform for clinical imaging, though Lunit focuses on single-modality clinical AI while Constellation targets whole-body MRI.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Q Bio

Preventive Health Diagnosticsq.bio

Q Bio operates a Clinical Digital Twin Platform that combines whole-body MRI, 120+ biomarkers, 163-gene genetic screening, wearable data, and physician review into a single longitudinal health record, delivered directly at its Redwood City clinic and through enterprise health partners.

What Q Bio does

Q Bio, founded in 2015 and headquartered in Redwood City, California, is a private health technology company building a Clinical Digital Twin Platform that integrates whole-body MRI, biomarker analysis, genetic screening, wearable data, and physician review into a single longitudinal health record. The core product is the Q Exam, a 75-minute in-clinic service priced at $3,495 per annual membership that captures non-contrast whole-body MRI imaging (9,500+ images across 10 sequences), 120+ blood and urine biomarkers, 163 clinically actionable genetic markers, vitals, and a 45-minute physician data review. The Q Bio Health Dashboard unifies these inputs into a longitudinal record organized across nine body systems, enabling year-over-year comparison for returning members. Constellation, the company's FDA 510(k)-cleared AI image-analysis software, performs automated organ and tissue segmentation from MRI scans and produces standardized measurements that make cross-visit comparison operationally viable.

Q Bio operates a dual go-to-market model. On the consumer side, individuals book the Q Exam directly at the Redwood City flagship clinic, which runs three appointment slots per day Monday through Friday. On the enterprise side, Q Bio partners with concierge medicine practices, executive health programs, longevity clinics, health systems, and employer member programs to deploy the Q Exam under the partner's brand, with Q Bio supplying the protocol, data infrastructure, and Dashboard layer. Enterprise deployments typically move from kickoff to live operation in approximately 4-6 months and are evaluated for international rollout on a partner-by-partner basis. The company does not accept insurance but the service qualifies for HSA/FSA reimbursement.

The company has raised approximately $91M in cumulative venture funding across rounds in 2016 ($7.5M), 2018 ($16.5M), 2020 ($40M), and 2024 ($27M), with investors including Andreessen Horowitz, Founders Fund, Khosla Ventures, Kaiser Permanente, and TELUS Global Ventures. Leadership combines Stanford, Harvard, MIT, UnitedHealth, Abbott, and Dexcom alumni. Q Bio holds no public listing and operates as Q Bio, Inc., a Delaware corporation.

Q Bio firmographics

Firmographics
Name
Q Bio
Legal name
Q Bio, Inc.
Website
https://q.bio
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Q Bio operates a Clinical Digital Twin Platform that combines whole-body MRI, 120+ biomarkers, 163-gene genetic screening, wearable data, and physician review into a single longitudinal health record, delivered directly at its Redwood City clinic and through enterprise health partners.
Ownership category
akta.pro rank

Q Bio industry classification

Industry
Product category
Preventive Health Diagnostics
NAICS
Medical Laboratories (621511), Diagnostic Imaging Centers (621512)
SIC
Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Whole-body MRI screening
  • Preventive health platform
  • AI medical imaging
  • Longitudinal health records
  • Biomarker genetic testing

Where Q Bio is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Q Bio business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Annual Q Exam Membership: Individual consumers pay $3,495 USD annually for access to the Q Exam, which includes the 75-minute whole-body MRI, biomarkers (120+), genetics (163 genes), vitals, physician review, and 45-minute Data Review session. This is a recurring annual subscription model where members return for follow-up exams that compound in longitudinal value.
  2. Enterprise Partner Deployment: Q Bio provides its protocol, data infrastructure, and Q Bio Health Dashboard to enterprise health partners who deploy the Q Exam within their own branded clinical environments. Partners provide the clinical setting, physician relationship, and member base while Q Bio supplies the underlying platform. Commercial terms vary by partner type, scope, and geography.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualIndividual Annual Membership at Redwood City Clinic

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Q Bio product offering

Product offering

Core offering

Q Bio operates the Q Exam, a single 75-minute in-clinic comprehensive physical examination that captures non-contrast whole-body MRI (9,500+ images across 10 sequences), 120+ blood and urine biomarkers, 163-gene genetic screening, wearable data integration, and a 45-minute board-certified physician Data Review. Results are unified in the Q Bio Health Dashboard, a longitudinal clinical interface powered by the FDA 510(k)-cleared Constellation AI image-analysis software, enabling year-over-year comparison of every subsequent exam.

Product overview

Q Bio delivers a unified preventive health platform consisting of two integrated products: the Q Exam and the Q Bio Health Dashboard, powered by Constellation (FDA-cleared AI image-analysis software). The Q Exam is the in-clinic service capturing whole-body MRI, 120+ biomarkers, 163 genetic markers, wearable data, and physician review in a single 75-minute visit. The Q Bio Health Dashboard is the longitudinal product surface that unifies all captured inputs into a comparative clinical record, organized by nine body systems, accessible to both patients and clinicians. The Dashboard compounds in value with each subsequent exam, enabling year-over-year comparison of imaging, biomarker trends, and findings. The platform is available directly at Q Bio's Redwood City clinic and through enterprise partner deployments where Q Bio serves as the infrastructure layer beneath the partner's brand.

Differentiator

Problem solved

Functional benefit

Brands

  • Q Exam: The comprehensive whole-body physical exam combining MRI, biomarkers, genetics, wearable data, and physician review.
  • Q Bio Health Dashboard
  • Constellation

Products and services

  • Q Exam A comprehensive in-clinic physical examination combining whole-body MRI (non-contrast, 9,500+ images across 10 sequences), 120+ blood and urine biomarkers, genetic screening of 163 clinically actionable genes, wearable device and prior medical record integration, and a 45-minute physician Data Review. Designed to establish a quantitative longitudinal health baseline captured in a single 75-minute visit for individual members and enterprise partner programs.
  • Q Bio Health Dashboard A longitudinal clinical interface that integrates imaging, biomarkers, genetics, wearable data, and physician-reviewed findings into a unified record organized by nine body systems. Delivered as both patient-facing and clinician-facing views, with year-over-year comparison capabilities, flagged out-of-range biomarkers, and shareable exports for the member's primary care team.
  • Constellation Q Bio's FDA 510(k)-cleared image-analysis software for whole-body MRI processing. Uses AI/machine-learning methods to segment anatomical regions (lung, liver, brain, and other structures), quantify key measurements, and organize results for radiologist and physician review. Standardized measurements enable direct comparison across visits.

Quantifiable outcome

  • 9,500+ images captured per whole-body MRI scan
  • +3 more outcomes

Companies that use Q Bio

Customer profile

Named customers1 record

Segments7 records

Ideal customer profiles5 records

Q Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Q Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Stanford UniversitycoreStrategic or Co-development PartnerMichael Snyder, PhD, Chair of Genetics and Professor of Genomics at Stanford University, serves as Scientific Advisor and Co-founder of Q Bio. He previously served as director of the Yale Center for Genomics and Proteomics. Academic partnership provides scientific expertise and research credibility for Q Bio's quantitative biology approach.
  • Harvard UniversitycoreStrategic or Co-development PartnerQ Bio's Chief Medical Officer & Co-founder is a former Harvard Medical School faculty member and board-certified radiologist. Garry Choy, MD/MBA, Co-founder, is also Harvard-affiliated. Harvard partnership provides medical leadership and clinical research credibility.
  • Massachusetts General HospitalcoreStrategic or Co-development PartnerClinical advisors with MGH affiliation provide medical expertise. MGH partnership contributes to Q Bio's clinical validation approach and reinforces the company's positioning within academic medical center circles.
  • Massachusetts Institute of Technology (MIT)coreStrategic or Co-development PartnerThomas Witzel, PhD, Chief Scientific Officer, has a key role in development of the Connectome MRI scanner and holds a PhD from Harvard-MIT Health Sciences & Technology. MIT affiliation contributes to Q Bio's MRI technology development.

Scale indicators2 records

Recent moves8 records

Expansion highlights6 records

Q Bio competitors and assessment

Company assessment

Direct peers

  • Prenuvo: Prenuvo offers whole-body MRI screening combined with optional blood biomarkers as a direct-to-consumer preventive health service. It is the most direct competitor to Q Bio's Q Exam, with overlapping target customer (health-conscious affluent adults) and similar MRI-plus-biomarker value proposition, though without Q Bio's FDA-cleared AI platform layer.
  • Ezra: Ezra provides whole-body MRI-based cancer and disease screening as a direct-to-consumer service using AI-assisted image analysis. It competes directly with Q Bio on MRI-based preventive screening for affluent consumers, with a similar AI-image-analysis value proposition though a narrower focus on oncology.
  • Human Longevity Inc: Human Longevity Inc (HLI) was a pioneer in combining whole-body MRI, whole-genome sequencing, and advanced biomarker testing into a comprehensive health assessment. It is a direct peer in offering integrated imaging-plus-genomic-plus-biomarker preventive health to high-net-worth and executive consumers.
  • Function Health: Function Health offers a comprehensive blood-based biomarker panel (100+ markers) via direct-to-consumer subscription with physician review and longitudinal tracking. It competes directly with Q Bio on the 'comprehensive preventive panel + physician review + longitudinal record' value proposition, though without the imaging component.
  • InsideTracker: InsideTracker provides blood-based biomarker analysis with personalized recommendations and longitudinal tracking for health optimization and longevity. It overlaps with Q Bio on the biomarker-tracking and longevity consumer segment, with similar longitudinal dashboard UX though narrower scope than Q Bio's MRI-based offering.
  • Forward Health: Forward Health operates membership-based preventive primary care clinics combining body scanning, blood testing, and AI-driven health insights. It is comparable to Q Bio as a tech-enabled preventive health membership model targeting affluent health-conscious consumers, with an owned-clinic distribution approach.
  • Fountain Life: Fountain Life operates preventive health and longevity centers offering whole-body MRI, advanced biomarker panels, and genetic testing to affluent members. It is comparable to Q Bio as a premium integrated preventive health platform targeting the same longevity-focused, high-net-worth consumer segment.

Broad incumbents

  • Tempus Labs: Tempus is a large precision medicine company applying AI to molecular and clinical data across oncology and beyond. While broader in scope and B2B-oriented, its AI-enabled diagnostics platform overlaps conceptually with Q Bio's Constellation AI image-analysis approach and longitudinal multimodal data positioning.
  • Color Health: Color Health combines genetic testing with preventive health screening and virtual care delivery to employers, health systems, and consumers. It overlaps with Q Bio on the genetic-screening + preventive-health value proposition and shares the enterprise partner channel strategy with employers and health systems.

Emerging players

  • Lunit: Lunit develops FDA-cleared AI medical imaging analysis software (notably for mammography and chest X-ray) sold to hospitals and radiology providers. It is comparable to Q Bio's Constellation as a regulatory-cleared AI image-analysis platform for clinical imaging, though Lunit focuses on single-modality clinical AI while Constellation targets whole-body MRI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Q Bio social profiles

Digital presence

Q Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Q Bio leadership team

Management profile

Number of profiles

Profiles6 records

Q Bio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Q Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q Bio

What does Q Bio do?

Q Bio operates the Q Exam, a single 75-minute in-clinic comprehensive physical examination that captures non-contrast whole-body MRI (9,500+ images across 10 sequences), 120+ blood and urine biomarkers, 163-gene genetic screening, wearable data integration, and a 45-minute board-certified physician Data Review. Results are unified in the Q Bio Health Dashboard, a longitudinal clinical interface powered by the FDA 510(k)-cleared Constellation AI image-analysis software, enabling year-over-year comparison of every subsequent exam.

Is Q Bio a public or private company?

Q Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Q Bio founded?

Q Bio was founded in 2015. It employs 11 to 50 people.

Where is Q Bio based?

Q Bio is headquartered in San Carlos, United States, in the North America region.

How does Q Bio make money?

Two revenue lines are on record. Annual Q Exam Membership is the primary driver. The others are enterprise Partner Deployment.

Who are Q Bio's main competitors?

Direct peers on record are Prenuvo, Ezra, Human Longevity Inc, Function Health, InsideTracker, Forward Health and Fountain Life. Broad incumbents are Tempus Labs and Color Health. Lunit is listed as an emerging player.

Does Q Bio have an API?

No public API is recorded for Q Bio.

What industry is Q Bio in?

Q Bio's product category is Preventive Health Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedInStartup Q Bio raises $27 million to build its own full-body scannerQ Bio has secured $27 million in funding from existing investors and new participant TELUS Global Ventures to develop a full-body MRI scanner. This investment aims to accelerate the commercialization of their technology, which provides quantified and reproducible health data for clinical monitoring.STATStartup Q Bio raises $27 million to build its own full-body scannerQ Bio raised $27 million in strategic funding from investors including Khosla Ventures, Andreessen Horowitz, and Founders Fund, with TELUS joining as a new investor. The funds will support manufacturing of its Mark I full-body scanner, which aims to be more comfortable, open, quick, and comprehensive than traditional MRI scanners.AuntMinnieQ Bio raises $27M in funding round for Mark I MRI scannerQ Bio has secured $27 million in strategic funding to accelerate the commercialization of its Mark I full-body MRI scanner. The device utilizes tensor field mapping technology to provide comprehensive anatomical data in 10 minutes without radiation or special room requirements. Key investors in this round include Telus Global Ventures, Khosla Ventures, Andreessen Horowitz, Founders Fund, and Kaiser Foundation Hospitals.HIT ConsultantQ Bio Secures $27M to Expand Full-Body MRI with Mark I ScannerQ Bio secured $27 million in strategic funding, with new investor TELUS Global Ventures joining existing backers like Khosla Ventures and Andreessen Horowitz, to accelerate the manufacturing and regulatory approval of its Mark I full-body MRI scanner. The Mark I utilizes proprietary Tensor Field Mapping technology to provide comprehensive quantitative anatomical data in a single 10-minute scan without radiation or enclosed spaces. This investment supports Q Bio's efforts to expand market launch preparations for this innovative medical imaging device.BBC Science Focus MagazineStar Trek-style scanner creates 'digital twin' to track your healthQBio, a US start-up led by CEO Jeff Kaditz, has developed a low-cost body scanner that creates 'digital twins' to track hundreds of biomarkers and detect disease progression early. The technology uses magnetic resonance and other sensors to perform full-body scans in under 15 minutes, aiming to revolutionize healthcare through proactive, data-led triage and personalized medicine.InvestmentreportsJeff Kaditz, Q BioJeff Kaditz discusses Q Bio, a company developing technology for comprehensive, non-invasive health monitoring and predictive modeling of biological states. The company is currently awaiting FDA approval for its full-body scan technology and is actively engaging with healthcare providers to integrate its digital twin platform into clinical practice.FierceBiotechOld MRI, new tricks: Q Bio puts forward quantifiable, reproducible scanning approachQ Bio is introducing a new 'quantifiable MRI' approach called tensor field mapping, which aims to provide reproducible and objective imaging data across different machines and patients. The company plans to integrate this technology into its upcoming Mark I MRI system and currently offers whole-body exams at its pilot site in California.American City Business JournalsKaiser Permanente invests in full-body scan technology company Q BioKaiser Permanente has invested in Q Bio, a company developing full-body scan technology aimed at improving diagnostic accuracy and efficiency. The investment supports the development of advanced imaging solutions designed to help prevent misdiagnoses and reduce healthcare costs.Amazon Web ServicesQ Bio: Creating the First Digital Twin Platform for Medical AnalysisQ Bio is developing a digital twin platform that combines a proprietary body scanner with cloud infrastructure to enable data-driven medical analysis and proactive healthcare. The company utilizes AWS services, including Amazon ECS and S3, to manage large-scale biomedical data processing and ensure reproducible results for researchers and doctors. This initiative aims to provide objective health diagnoses by tracking biomarker changes over time.HIT ConsultantQ Bio Launches Clinical “Digital Twin” Platform, Whole Body ScannerQ Bio unveiled its Q Bio Gemini digital twin platform and the Mark I whole-body scanner, which scans in 15 minutes without radiation. The company announced a total capital of over $80 million, including Series B funding led by Andreessen Horowitz, to expand access to its preventive care technologies.